Zhongguancun Shuimu Medical Completes Hundreds of Millions RMB Series B Financing; Phrontline Biopharma Doses First Patient in Phase I Trial of TJ101

Med-Fine FamilyFinancing Progress

Med-Fine FamilyResearch Progress

1.Orange Sails MedicalMedicineBest wishesCongratulationsAvenzo Therapeutics Nectin4/TROP2Bispecific AntibodyADCObtainFDAClinical Trial Permit

Shanghai,2025Year9Month3Day——VelaVigo (Cayman) LimitedShanghai Orange Sail Pharmaceutical Co., Ltd., a subsidiary, congratulates its partnerAvenzo TherapeuticsThe company is based on the potential best-in-class jointly developed by both parties.Nectin4/TROP2Bispecific Antibody Drug ConjugatesAVZO-103Has obtained the United StatesFDANew Drug Clinical Trials (IND) Application for approval. This timeINDApproved based on the agreement between the two parties on2024Year11Month18Strategic cooperation reached on [date].AvenzoHas exercised againstAVZO-103The exclusive option to obtain the global development, production, and commercialization rights of the drug outside Greater China.Learn More

2.ArtivilaAnnouncement of the Successful Completion of Phase I Clinical Study of ARD-885 New Drug

Recently, Artivila announced that the company has developed a chemical small molecule with a novel target for treating autoimmune diseases.1New Drug ClassARD-885Successfully Completed in Healthy SubjectsIPhase clinical research, and achieved positive results, marking another important milestone for Artivila in the innovative drug development journey.Learn More

3.MabworksMIL62TreatmentNMOSDClinicalIIIExpected results inECTRIMS 2025InLBAHeavyweight Release in Oral Report Format

Beijing Mabworks Biotechnology Co.,Ltd announced that, in2025Year9Month24Date26Day of the41The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) During, the third generationCD20AntibodyMIL62Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD) ClinicalIIIThe research results of the period were selected for the conference's latest breakthrough abstract (Late Breaking Abstracts，LBA) Oral Presentation Session.Learn More

4.MabworksMIL62The second new drug marketing application - for the treatment of primary membranous nephropathyNDAAccepted

Recently, Beijing Mabworks Biotechnology Co., Ltd. announced the self-developed innovative third-generationCD20AntibodyMIL62Treatment of Primary Membranous Nephropathy (PMN) New Drug Marketing Authorization Application (NDA) has been accepted by the National Medical Products Administration, becoming the world's first targetedPMNTherapeuticNDADrug Application.Learn More

5.ToreMed PharmaAnnouncementTJ101First Patient Dosed in Phase I Clinical Trial

According to PR Newswire, Avenzo Therapeutics (Phrontline Biopharma）9Month19Announced on [Date], its core productTJ101The first patient has been dosed in a Phase I clinical trial. The drug utilizes the company's proprietary linker.-Drug Technology, TargetedEGFR/B7-H3Dual-target, marking a new generation of antibody-drug conjugates (ADC) Important progress has been made in the research and development.Learn More

6.EnotronEngineered ExosomesMVR-EX105First Release of Healthy Population Data-Breakthrough in Topical Fat Reduction and Muscle Gain

Avenzo Therapeutics recently announced that its leading engineered exosome candidate productMVR-EX105（“EX105"") Selected2025International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Annual Conference Poster Presentation.Learn More

7.Zhuo Dao MedicalDORA®Bedside Active-Passive Rehabilitation Training System Successfully Approved for Medical Device Registration Certificate

2025Year9Month10Day, ZD Medical®Dora®The bedside active-passive rehabilitation training system has been approved by the Shanghai Medical Products Administration and has successfully obtained the Class II Medical Device Registration Certificate of the People's Republic of China, with the registration certificate number: Hu Med Reg No.20252190402。Learn More

8.Zhuo Dao Medical®Intelligent Rehabilitation Research Published at the World's Top Academic Conference in Robotics and AutomationICRA2025

Zhuo Dao Medical®The rehabilitation robot research and development team, jointly formed by Fudan University, University of Shanghai for Science and Technology, and the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital), has made breakthrough progress in the research direction of intelligent human-computer interaction. The related research achievements have been published in the paper titled "Gaze and Go: Harnessing Visual Attention Valence in Upper-Limb Robotic Rehabilitation With Tailored Gamification and Eye Tracking for Neuroplasticity》 in the form of2025Year1Month31Day of the World Robot Summit2025 IEEE International Conference on Robotics and Automation(ICRA 2025) Receive, the meeting was held on5Month19Day-5Month23The conference was held in Atlanta, USA, where a representative of the project team gave a video oral presentation. The paper has been9Month2Officially included and published online on the 18th.Learn More

9.Westlake UniversityGuo Tiannan's Team from the Medical College Collaborates with Global Scientists to Propose a New Framework for Standardizing Blood Proteomics

2025Year9Month23On a certain day, Professor Tianan Guo from the Medical College of West Lake University and the University of Greifswald, Germany Uwe Völker Professor, USA Cedars Sinai Medical Center Jennifer Van Eyk Professor and KTH Royal Institute of Technology Jochen M. Schwenk Led by a professor, scientists from dozens of top institutions worldwide have joined forces inNature GeneticsPublished a landmark opinion article. They conducted an in-depth analysis of the current standardization challenges in blood proteomics research and systematically proposed an actionable solution for the first time.Learn More

03

Med-Fine FamilyBusiness Breakthrough

Recently, Gu Yabin, Deputy Director of Suzhou Municipal Medical Insurance Bureau, and Zou Cao, Director of the Department of Cardiology at the First Affiliated Hospital of Soochow University, visited Aicompulse Medical for an inspection tour. The visit provided an in-depth understanding of the innovative progress in cutting-edge electrophysiological technologies for the heart produced in China, and facilitated discussions on the effective collaboration between clinical needs, technological innovation, and policy support, injecting new momentum into the high-quality development of local medical enterprises in Suzhou.Learn More

3.The First Affiliated Hospital of Soochow University: Among the First Batch in China to LaunchAicompulse MedicalPFASuccessful Clinical Application of Surgery

Recently, Director Jiang Tingbo and Director Zou Cao from the Department of Cardiology at the First Affiliated Hospital of Soochow University led their team to successfully complete the first batch of procedures in China using the Aikangmai medical device.AccuPulseClinical Application of Cardiac Pulse Ablation System.AccuPulseThe cardiac pulse ablation system, with its7.5FMultiple technological breakthroughs, such as ultra-fine adjustable loop diameter, intelligent impedance contact indication, and integrated mapping, modeling, and ablation, are redefining the new standard for atrial fibrillation pulsed field ablation treatment, providing an optimal solution for atrial fibrillation interventional therapy.Learn More

4.Aushine MedicalInnovative Technology Lights UpCUA2025, The 32nd Urology Congress Concludes in Splendor

2025Year9Month4-07Date, The 32nd Annual Meeting of Urology of Chinese Medical Association (CUA2025) Opens in Dalian. At this grand event, Aosheng Medical重磅亮相其彩色多普勒超声系统UGU-300AndUGU-600, becoming the center of attention throughout the venue. The booth attracted numerous authoritative experts and peers in the urology field to stop and engage in discussions.Learn More

5.Ensheng MedicalV-Mixtent®Venous Stent System DebutsAPAC`, Highly Praised by International Experts`

Ensheng Medical Appears at This SessionAPACAnd specially invited the famous Indonesian vascular surgery expertRaden SuhartonoDoctor (hereinafter referred to asTonoPh.D.), jointly presentedV-Mixtent®The innovative breakthrough of the venous stent system highlights the excellent performance of this China-made venous stent in treating venous obstructive diseases.Learn More

6.Ensheng MedicalV-Mixtent®Successful Export of Venous Stents to Malaysia Opens a New Chapter in International Business

2025Year9Month, Ensheng Medical Company's Core ProductV-Mixtent®Successful Export of Venous Stents to Malaysia Marks a Zero Breakthrough in International Business, Signifying Ensheng Medical's Official Entry into the International Market and the Opening of a New Chapter in Global Operations.Learn More

7.ChosenMedPerfectly PassedCAP NGSST-A 2025Competency Assessment Certification

Recently, the College of American Pathologists(CAP, College of American Pathologists) Published2025 CAP-NGSST-AProficiency Testing Assessment Report: Chasing Medicine Successfully Passes with Full MarksCAPThe renewed comprehensive recognition of ChosenMed Lab's stable, reliable, and consistently accurate testing capabilities signifies that ChosenMed's diagnostic quality and standards remain among the highest internationally.Learn More

8.ChosenMedPerfect Score Passed2025China National External Quality Assessment for Bioinformatics Analysis of Somatic Mutation High-Throughput Sequencing in Tumors

Recently, the National Center for Clinical Laboratories of the National Health Commission announced2025Results of the National External Quality Assessment for Bioinformatics Analysis of Somatic Mutation Detection in Tumors by High-Throughput Sequencing: ChosenMed Achieves a Perfect Score in This External Quality Assessment.2020Since achieving a perfect score in the proficiency testing program for the first time, ChosenMed has consecutively received perfect scores for six years in this assessment, once again demonstrating the company's accuracy and stability in testing as well as its robust technical capabilities in bioinformatics analysis.Learn More

Med-Fine Family Business Cooperation

1.The Faculty of Dentistry, The University of Hong KongChuangqi MedicalBoth Parties Deepen Strategic Cooperation in the Lingual Orthodontics Field

2025Year8Late in the month, from the Faculty of Dentistry, The University of Hong Kong (HKU Faculty of Dentistry) Teachers' representatives visited Guangzhou Chuangqi Medical Technology Co., Ltd. This visit is6The in-depth exchange once again took place after the two parties officially signed the strategic cooperation agreement in the month, aiming to further deepen the strategic cooperation in the field of lingual orthodontics. Detailed discussions were held regarding the implementation of further cooperation moving forward.Learn More

Med-Fine FamilyIndustry Honors

1.SaiFu Pharmaceuticals Honored with the "Outstanding Supplier" Award by ImmuneON

2.West Lake Omics Selected2025ChinaAIFuture Unicorn Companies Going OverseasTOP100List

3.MicroMedicine Ranks on Deloitte China's "Yizhuang High-Tech High-Growth"10"Strong"

4.XinCheng Medical Honored CCI Top Ten Innovative Enterprises of the Decade

5.Heart Power Medical Selected as a Potential Unicorn Enterprise in Jiangsu Province for Five Consecutive Years